DALLAS, May 16, 2005 (PRIMEZONE) -- TalkingStocks.com released an exclusive interview with Raymond J. Talarico, CEO for MEDirect Latino, Inc. (Pink Sheets:MLTO). The interview was conducted for TalkingStocks.com by the well known host of Traders Nation, Kurt Schemers.
Mr. Talarico discusses the formation of the company and how the management team saw a great need in providing diabetic products to Medicare eligible Hispanics. While a few companies provide similar diabetic products to the general market, the special niche that MEDirect Latino, Inc. is targeting is more prone to diabetes than the general population, and would benefit greatly from these products.
Mr. Talarico further discusses the potential market, the likely demand, and how the company has setup an infrastructure to meet that demand.
To listen to the exclusive TalkingStocks.com interview with Raymond Talarico, CEO of MEDirect Latino, Inc., please visit:
http://talkingstocks.com/interviews/MLTO_051705.php
Registration is free.
A reminder to investors and others interested in MEDirect Latino, Inc., the company will conduct an investor conference call later today, Tuesday, May 17, 2005, hosted by company CEO, Raymond J. Talarico.
Instructions for hearing the conference call:
To hear the conference call as it takes place: Call 1-800-434-1335 in the United States or Canada or; Call 1-404-920-6620 in the Atlanta Area or Internationally Pin Code: 098756 Exclusive: For Expedited Entry into the Conference: Please register via this link for your Direct Access 800 number. http://www.AccuConference.com/MLTO
About MEDirect Latino:
MEDirect Latino (Pink Sheets:MLTO), http://www.medirectlatino.org, is a rapidly growing, uniquely positioned provider of direct-to-consumer Medicare reimbursed medical products focused exclusively on chronic diseases afflicting the Hispanic community in the United States and Puerto Rico. MEDirect is the only company positioned to serve the U.S. Hispanic healthcare market as a direct-to-consumer Medicare provider on an authentically national level. The Company's current focus is the distribution of products for the treatment of Type II diabetes specifically because of its disproportionate impact and increasing diagnosis rate within the US Hispanic population, noting an incidence of 120% higher than among non-Hispanic whites. Type II diabetes was also targeted because of its unique status within the Medicare reimbursement regime and because of its high degree of correlation to other chronic conditions such as high blood pressure and heart disease. These other conditions represent considerable future market potential that will allow MEDirect to efficiently scale its model by leveraging its existing client base and infrastructure.
The current Hispanic market for MEDirect's products is conservatively estimated at approximately $650MM in the continental United States. The size of the opportunity is understated by such figures as an estimated 925,000 of the over 3.1 million Hispanics in the United States over 65 eligible to receive Medicare benefits are currently collecting these benefits with an estimate that over 1.4 million of those Medicare-eligible Hispanics have diabetes (implying a potential continental U.S. market for MEDirect products of approximately $1 billion).
About TalkingStocks.com:
StockGuru.com and TalkingStocks.com are two key destinations on the internet for those seeking information on smallcap and microcap companies. The web sites feature companies in Profile Campaigns, Key Executive Interviews, email alerts and special reports authored by our financial writers. The web sites set the standard for communication with investors. To feature a company or to get more information, please contact our publisher, John Pentony, for more information (Telephone: 972-865-1401; Email: publisher@stockguru.com).
Forward-Looking Statements:
Statements about the Company's future expectations, including future revenues and earnings, and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as the term is defined in the Private Litigation Reform Act of 1995. The Company's actual results could differ materially from expected results. The Company undertakes no obligation to update forward-looking statements to reflect subsequently occurring events or circumstances. Should events occur which materially affect any comments made within this press release; the Company will appropriately inform the public.
Disclosure: Pentony Enterprises LLC and TalkingStocks.com LLC have been compensated $6,000 and 12,000 restricted shares by a third party company for profile coverage. Neither TalkingStocks.com, LLC, nor Pentony Enterprises, LLC, are registered investment advisers or broker/dealers. TalkingStocks.com, LLC and Pentony Enterprises, LLC makes no recommendation that the purchase of securities of companies profiled in this website is suitable or advisable for any person or that an investment such securities will be profitable.